Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 6Unknown 3Not yet recruiting 3Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Recurrence 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Acute Lung Injury 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × pirfenidone × Clear all
NCT04467723 2026-01-28

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

University of Kansas Medical Center

Phase 1/2 Recruiting
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT05704166 2025-08-08

PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients

Fujian Medical University Union Hospital

Phase 2 Recruiting
214 enrolled
Breast

Breast Neoplasms, Acute Lung Injury

Data powered by HemOnc (CC BY 4.0) Colophon âš¡